{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:22:44Z","timestamp":1786980164159,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Langenbecks Arch Surg"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gastric cancer remains a major clinical challenge with poor prognosis. This study investigated survival outcomes based on treatment strategy, tumor stage, and histology in Danish gastric cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From January 2013 to December 2021, 2,156 gastric cancers were registered in the Danish Esophagogastric Cancer Group database, covering 99% of national cases. Data were analyzed for patients with intestinal and diffuse-type cancers. Survival was assessed using Kaplan\u2013Meier curves and Cox regression, adjusting for tumor stage, treatment, and demographics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median survival was significantly higher with surgery\u2009\u00b1\u2009perioperative chemotherapy (SCT) than with palliative treatment. For the intestinal-type cancers, SCT resulted in a median survival of 45.2\u00a0months (95% CI [35.4\u201355.1]) versus 5.1\u00a0months (95% CI [4.6\u20135.7]) with palliative treatment. Patients with diffuse type, treated with SCT had a median survival exceeding 128\u00a0months, compared with 6.3\u00a0months (95% CI [5.2\u20137.5]) with palliative treatment. Patients receiving epirubicin based CT had a lower risk of death (HR 0.74,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04) compared with upfront surgery, while FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) similarly reduced the risk of death (HR 0.69,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04). No significant difference was observed between the two CT regimens. Palliative CT and radiotherapy improved survival over best supportive care (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Advanced tumor stage was associated with worse survival, while the histological subtype had no impact on overall survival outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study emphasizes the survival benefit of multimodal treatment strategies, especially surgery combined with perioperative CT. Palliative interventions also improved outcomes in advanced disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00423-025-03861-y","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T02:54:03Z","timestamp":1761188043000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Stage-dependent survival in gastric cancer: a Danish nationwide cohort study"],"prefix":"10.1007","volume":"410","author":[{"given":"Oliver N\u00f8rholm","family":"Kempf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Bech Jellesmark","family":"Thorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaj","family":"Nerup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Kj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Sanberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Siemsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarunas","family":"Dikinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra Singh","family":"Garbyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"B\u00e6ksgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Patrick","family":"Achiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"issue":"3","key":"3861_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"3861_CR2","unstructured":"DECG (2023) Danish Esophago- Gastric Cancer group annual report 2022 [Internet]. Available from: https:\/\/www.sundhed.dk\/content\/cms\/85\/4685_degc-aarsrapport-2022.pdf. Accessed 16 Apr 2024"},{"issue":"1","key":"3861_CR3","doi-asserted-by":"publisher","first-page":"23142","DOI":"10.1038\/s41598-021-02391-z","volume":"11","author":"HM Hu","year":"2021","unstructured":"Hu HM, Tsai HJ, Ku HY, Lo SS, Shan YS, Chang HC et al (2021) Survival outcomes of management in metastatic gastric adenocarcinoma patients. Sci Rep 11:23142","journal-title":"Sci Rep"},{"key":"3861_CR4","doi-asserted-by":"crossref","unstructured":"Gospodarowicz MK, Brierley JD, Wittekind C (eds) (2017) TNM classification of malignant tumours, 8th edn. Wiley-Blackwell, Hoboken, pp 57\u201362","DOI":"10.1002\/9780471420194.tnmc10.pub3"},{"issue":"12","key":"3861_CR5","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1136\/gutjnl-2014-308915","volume":"64","author":"A Colquhoun","year":"2015","unstructured":"Colquhoun A, Arnold M, Ferlay J, Goodman KJ, Forman D, Soerjomataram I (2015) Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut 64(12):1881\u20131888","journal-title":"Gut"},{"issue":"2016","key":"3861_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ijsu.2016.09.080","volume":"35","author":"Y Muneoka","year":"2016","unstructured":"Muneoka Y, Akazawa K, Ishikawa T, Ichikawa H, Nashimoto A, Yabusaki H et al (2016) Nomogram for 5-year relapse-free survival of a patient with advanced gastric cancer after surgery. Int J Surg 35(2016):153\u20139. https:\/\/doi.org\/10.1016\/j.ijsu.2016.09.080","journal-title":"Int J Surg"},{"issue":"7","key":"3861_CR7","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.ejso.2015.03.225","volume":"41","author":"XJ Wu","year":"2015","unstructured":"Wu XJ, Miao RL, Li ZY, Bu ZD, Zhang LH, Wu AW et al (2015) Prognostic value of metastatic lymph node ratio as an additional tool to the TNM stage system in gastric cancer. Eur J Surg Oncol 41(7):927\u2013933","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"3861_CR8","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1186\/1471-2407-14-663","volume":"14","author":"Z Zhu","year":"2014","unstructured":"Zhu Z, Sun X, Wang J, Sun Z, Wang Z, Zheng X et al (2014) Histopathology-based prognostic score is independent prognostic factor of gastric carcinoma. BMC Cancer 14:663","journal-title":"BMC Cancer"},{"issue":"SUPPL.1","key":"3861_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s10120-011-0112-7","volume":"15","author":"HR Raziee","year":"2012","unstructured":"Raziee HR, Cardoso R, Seevaratnam R, Mahar A, Helyer L, Law C et al (2012) Systematic review of the predictors of positive margins in gastric cancer surgery and the effect on survival. Gastric Cancer 15(SUPPL.1):116\u2013124","journal-title":"Gastric Cancer"},{"issue":"3","key":"3861_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.suronc.2014.06.001","volume":"23","author":"C Okholm","year":"2014","unstructured":"Okholm C, Svendsen LB, Achiam MP (2014) Status and prognosis of lymph node metastasis in patients with cardia cancer \u2013 a systematic review. Surg Oncol 23(3):140\u2013146","journal-title":"Surg Oncol"},{"issue":"2","key":"3861_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10120-019-00997-x","volume":"23","author":"EC Gertsen","year":"2020","unstructured":"Gertsen EC, Goense L, Brenkman HJF, van Hillegersberg R, Ruurda JP (2020) Identification of the clinically most relevant postoperative complications after gastrectomy: a population-based cohort study. Gastric Cancer 23(2):339\u2013348","journal-title":"Gastric Cancer"},{"issue":"7","key":"3861_CR12","first-page":"791","volume":"16","author":"DH Henry","year":"2008","unstructured":"Henry DH, Viswanathan HN, Elkin EP, Traina S, Wade S, Cella D (2008) Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S. Support Care Cancer 16(7):791\u2013801","journal-title":"Support Care Cancer"},{"issue":"4","key":"3861_CR13","first-page":"441","volume":"53","author":"CB Pedersen","year":"2006","unstructured":"Pedersen CB, G\u00f8tzsche H, M\u00f8ller J\u00d8, Mortensen PB (2006) The Danish civil registration system: a cohort of eight million persons. Danish Medical Bulletin 53(4):441\u20139","journal-title":"Danish Medical Bulletin"},{"issue":"5","key":"3861_CR14","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","volume":"13","author":"S Cuschieri","year":"2019","unstructured":"Cuschieri S (2019) The STROBE guidelines. Saudi J Anaesth 13(5):S31\u2013S34","journal-title":"Saudi J Anaesth"},{"key":"3861_CR15","unstructured":"DEGC (2023) DEGC-Guidelines: Surgical treatment of gastric adenocarcinoma [Internet]. Available from: https:\/\/degc.dk\/wpcontent\/uploads\/2023\/02\/DEGC_Esop_vent_pato_diagos_stad_v.2.0_AdmGodk_27022023.pdf.\u00a0Accessed 18 Jun\u00a02024"},{"key":"3861_CR16","unstructured":"DEGC (2021) DEGC - treatment of incurable Gastric cancer [Internet]. Available from: https:\/\/degc.dk\/wp-content\/uploads\/2021\/03\/DEGC_diss_ventr_canc_AdmGodk051020.pdf. Accessed 19 Jun\u00a02024"},{"key":"3861_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","volume":"76","author":"ID Nagtegaal","year":"2020","unstructured":"Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P et al (2020) The 2019 WHO classification of tumours of the digestive system. Histopathology 76:182\u20138. https:\/\/doi.org\/10.1111\/his.13975","journal-title":"Histopathology"},{"issue":"1","key":"3861_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11\u201320","journal-title":"N Engl J Med"},{"issue":"13","key":"3861_CR19","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","volume":"29","author":"M Ychou","year":"2011","unstructured":"Ychou M, Boige V, Pignon JP, Conroy T, Bouch\u00e9 O, Lebreton G et al (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29(13):1715\u20131721","journal-title":"J Clin Oncol"},{"issue":"10184","key":"3861_CR20","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet 393(10184):1948\u20131957","journal-title":"Lancet"},{"issue":"63","key":"3861_CR21","doi-asserted-by":"publisher","first-page":"322","DOI":"10.2340\/1651-226X.2024.35431","volume":"14","author":"K Egebjerg","year":"2024","unstructured":"Egebjerg K, Andersen TS, B\u00e6ksgaard L, Garbyal R, Siemsen M, Achiam M et al (2024) Implementation of perioperative FLOT compared to ECX\/EOX chemotherapy regimens in resectable esophagogastric adenocarcinomas: an analysis of real-world data. Acta Oncol 14(63):322\u2013329","journal-title":"Acta Oncol"},{"key":"3861_CR22","doi-asserted-by":"crossref","unstructured":"Wagner AD, Syn NLX, Moehler M, Grothe W, Yong WP, Tai BC et al (2017) Chemotherapy for advanced gastric cancer. Vol. 2017, cochrane database of systematic reviews. John Wiley and Sons Ltd","DOI":"10.1002\/14651858.CD004064.pub4"},{"key":"3861_CR23","unstructured":"DEGC (2020) DEGC-guidelines: oncological treatment of patients with curable carcinomas of the esophagus, gastroesophageal junction (GEJ), and stomach (december). Available from: https:\/\/degc.dk\/wp-content\/uploads\/2023\/02\/DEGC_Onko_bh_pati_kur_-karcin_esop_ventrikel_v.2.0_AdmGodk_010223.pdf. Accessed 26 Mar 2025"},{"key":"3861_CR24","doi-asserted-by":"publisher","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, R\u00fcschoff J, Kang YK (2010) ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X","DOI":"10.1016\/S0140-6736(10)61121-X"},{"issue":"10294","key":"3861_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398(10294):27\u201340","journal-title":"Lancet"},{"issue":"2","key":"3861_CR26","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S2468-1253(17)30363-1","volume":"3","author":"MG Penniment","year":"2018","unstructured":"Penniment MG, De Ieso PB, Harvey JA, Stephens S, Au HJ, O\u2019Callaghan CJ et al (2018) Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). Lancet Gastroenterol Hepatol 3(2):114\u201324","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3861_CR27","doi-asserted-by":"crossref","unstructured":"Tey J, Yang Soon Y, Yao Koh W, Nang Leong C, Ai Choo B, Ho F et al (2017) Palliative radiotherapy for gastric cancer: a systematic review and meta-analysis. Oncotarget 8(15):25797\u201325805. https:\/\/www.impactjournals.com\/oncotarget\/","DOI":"10.18632\/oncotarget.15554"},{"issue":"28","key":"3861_CR28","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1200\/JCO.2012.42.6635","volume":"30","author":"S Taghavi","year":"2012","unstructured":"Taghavi S, Jayarajan SN, Davey A, Willis AI (2012) Prognostic significance of signet ring gastric cancer. J Clin Oncol 30(28):3493\u20133498","journal-title":"J Clin Oncol"},{"issue":"5","key":"3861_CR29","first-page":"1093","volume":"154","author":"C Gronnier","year":"2013","unstructured":"Gronnier C, Messager M, Robb WB, Thiebot T, Louis D, Luc G et al (2013) Is the negative prognostic impact of signet ring cell histology maintained in early gastric adenocarcinoma? Surgery (United States) 154(5):1093\u20131099","journal-title":"Surgery (United States)"},{"issue":"2","key":"3861_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10120-018-0860-8","volume":"22","author":"YC Kao","year":"2019","unstructured":"Kao YC, Fang WL, Wang RF, Li AFY, Yang MH, Wu CW et al (2019) Clinicopathological differences in signet ring cell adenocarcinoma between early and advanced gastric cancer. Gastric Cancer 22(2):255\u2013263","journal-title":"Gastric Cancer"},{"key":"3861_CR31","unstructured":"DEGC guidelines: pathology, diagnostic methods, and staging of esophageal and stomach cancer [Internet]. Available from: https:\/\/degc.dk\/wp-content\/uploads\/2023\/02\/DEGC_Esop_vent_pato_diagos_stad_v.2.0_AdmGodk_27022023.pdf. Accessed 26 Mar 2025"}],"container-title":["Langenbeck's Archives of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00423-025-03861-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00423-025-03861-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00423-025-03861-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T02:54:07Z","timestamp":1761188047000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00423-025-03861-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3861"],"URL":"https:\/\/doi.org\/10.1007\/s00423-025-03861-y","relation":{},"ISSN":["1435-2451"],"issn-type":[{"value":"1435-2451","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The paper is not based on any previous communication to a society or meeting.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous communication"}}],"article-number":"308"}}